Anzeige
Mehr »
Dienstag, 21.07.2026 - Börsentäglich über 12.000 News
42 Proben im Labor - Jetzt beginnt die spannendste Phase für diese Wolfram-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BDZ | ISIN: KYG2545C1042 | Ticker-Symbol: C68
Frankfurt
20.07.26 | 08:06
12,000 Euro
-3,23 % -0,400
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CRESCENT BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
CRESCENT BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,50013,90020.07.

Aktuelle News zur CRESCENT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCrescent Biopharma, Inc.: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares77WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
► Artikel lesen
MiCrescent Biopharma prices $125M public offering at $14.50/share1
CRESCENT BIOPHARMA Aktie jetzt für 0€ handeln
MiCrescent Biopharma, Inc.: Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants1
14.07.Crescent Biopharma launches public offering of ordinary shares1
14.07.Crescent Biopharma startet öffentliches Aktienangebot1
14.07.Crescent Biopharma, Inc.: Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants1
14.07.CRESCENT BIOPHARMA, INC. - 8-K, Current Report3
26.06.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards2
23.06.Cantor Fitzgerald reiterates Crescent Biopharma stock rating4
22.06.CRESCENT BIOPHARMA, INC. - 10-Q/A, Quarterly Report1
11.06.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards2
03.06.CRESCENT BIOPHARMA, INC. - 8-K, Current Report1
29.05.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards1
21.05.Crescent Biopharma to present CR-001 trial data at ASCO meeting2
21.05.Crescent Biopharma, Inc.: Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting169ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple...
► Artikel lesen
12.05.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards1
29.04.Crescent Biopharma, Inc.: Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights273ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination...
► Artikel lesen
29.04.CRESCENT BIOPHARMA, INC. - 10-Q, Quarterly Report-
24.04.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards2
27.03.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards10
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1